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Relapse is the main cause of mortality in patients with acute myeloid leukemia (AML) after
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Adverse cytogenetic or
molecular risk factors, as well as refractory disease or persistent measurable residual
disease (MRD) at the time of transplantation are associated with an increased risk of
recurrence. Salvage therapy for AML relapse after allo-HSCT is often limited to
chemotherapy, donor lymphocyte infusions and/or second transplants and is rarely
successful. Effective post-transplant preventive intervention in high risk AML may be
crucial. The most frequent and promising approach is the use of post-transplant
maintenance with hypomethylating agents or with FLT3 tyrosine kinase inhibitors when
the target is present. Moreover, IDH1/IDH2 inhibitors and BCL-2 inhibitors in combination
with other strategies are promising approaches in the maintenance setting. Here we
summarize the current knowledge about the preemptive and prophylactic use of
pharmacologic agents after allo-HSCT to prevent relapse of AML.
Keywords: acute myeloid leukemia, stem cell transplantation, allogeneic, relapse, prevention, hypomethylating agents

INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently considered the optimal
curative treatment option for patients with unfavorable risk acute myeloid leukemia (AML) (1–3).
The implementation of non-myeloablative conditioning regimens and the improvement in
supportive care has led to decrease in the transplant-related mortality (TRM) and to signiﬁcant
increase in the number of transplant candidates, including older patients and/or those with
comorbidities (4, 5). However, reduced-intensity conditioning (RIC) is associated with higher
rate of relapse (6). Allo-HSCT is generally recommended when the beneﬁt of relapse reduction
outweighs the risk of non-relapse mortality (NRM)/morbidity and this is based on the assessment of
cytogenetic and molecular genetic features as well as donor, patient, and transplant-related factors
(7–10). This includes intermediate or high-risk cytogenetic/molecular disease groups deﬁned by the

1

November 2020 | Volume 10 | Article 596134

Antar et al.

AML Relapse Prevention After Allo-HSCT

maintenance post-transplant is supported by the observation of
an anti-leukemic synergism between sorafenib and alloreactive
donor cells (36, 37). One recent study demonstrated that
sorafenib promotes GVL activity in mice and humans through
interleukin-15 production in FLT3-ITD leukemia cells (38).
Here, we summarize the clinical data on a number of agents
being studied as maintenance/preemptive therapies after alloHSCT in AML focusing mainly on TKIs (FLT3 inhibitors) and
HMAs (azacitidine and decitabine).

2017 European Leukemia Net (ELN) guidelines, achievement of
complete remission (CR) after more than one induction
chemotherapy, refractory disease and the presence of pretransplant measurable residual disease (MRD) positivity (7,
11, 12).
Disease relapse in transplanted patients in ﬁrst CR (CR1)
occurs in 30%–40% of cases and harbors a particular poor
prognosis if it occurs in the ﬁrst 6 months post-transplant
(13). Relapse rates are even higher among patients who
undergo allo-HSCT beyond CR1 or those with refractory
disease (14, 15).
The treatment options for AML patients who relapse after
transplant are very limited and highly depend on the patient
performance status at the time of relapse (16). Commonly used
treatment options for patients who are candidates for intensive
therapy are salvage chemotherapy, often associated with donor
lymphocyte infusion (DLI), allogeneic stem cell boost, or even
second allo-HSCT from the same or different donor (17–24). In
contrast, patients who are not eligible for intensive therapy are
usually offered low intensity chemotherapy, hypomethylating
agents (HMA), targeted therapies, participation in clinical
trials, and withdrawal of immunosuppression or supportive
care, all aiming at controlling the disease rather than achieving
remission (25–27).
Salvage treatments post-allo-HSCT can induce remissions
only in a minority of patients (20%) and the 2-year overall
survival (OS) rates are usually below 20% (28–30). Alternatively,
preventive strategies have been studied to reduce the incidence of
relapse including the use of myeloablative conditioning (MAC),
prophylactic DLI, graft manipulation, early withdrawal of
immunosuppression or intensive surveillance. Intensiﬁcation of
conditioning regimen by using MAC is associated with a lower
relapse rate but with higher TRM. Thus, there is no difference in
OS when MAC or RIC are used in allo-HSCT for AML (31).
Prophylactic DLI is associated with a decrease in the relapse rate
at the expense of more graft-versus-host disease (GVHD) and
therefore an increased morbidity and mortality (32).
The low efﬁcacy of these strategies to prevent post-transplant
relapse led to the introduction of alternative approaches such as
prophylactic pharmacological interventions for patients with
unfavorable risk, or preemptive strategies for patients with risk
of imminent recurrence indicated by MRD positivity by ﬂow
cytometry, cytogenetic testing, molecular analysis or loss of
donor chimerism. The ideal maintenance agent should target
an active driver pathway, such as tyrosine kinase inhibitors
(TKIs) targeting FLT3 (such as sorafenib and midostaurin) or
HMA (i.e., azacitidine and decitabine). These agents have an
acceptable non-hematologic toxicity with manageable drug–drug
interactions. Moreover, they enhance the graft-versus-leukemia
effect (GVL) with non-signiﬁcant effect on GVHD. For instance,
in vitro and murine studies showed that HMAs has an important
immunologic effect after transplantation in expanding
circulating T regulatory (Tregs)/natural killer (NK) cells and
up-regulating the expression of tumor antigens on leukemic
blasts leading to increased GVL effect without increasing the
risk of GVHD (33–35). Moreover, the use of FLT3 inhibitors as

Frontiers in Oncology | www.frontiersin.org

MRD Assessment
There are two approaches to reduce the risk of frank AML relapse
following allo-HSCT, prophylactic and preemptive strategies.
Prophylactic strategies are deﬁned as the initiation of treatment in
the absence of any measurable disease after transplant. Prophylactic
therapy is given to patients with high risk of relapse in the aim to
eradicate residual malignant cells which are undetectable by
currently available monitoring techniques. In contrast, preemptive
strategies are initiated for patients with risk of imminent relapse
presenting as any evidence of disease activity at MRD level to
prevent frank hematological relapse.
MRD persistence at transplant has been identiﬁed as an
independent and strong risk factor for post-transplant relapse
that can be at least partially overcome by additional intervention
such as augmented conditioning (7, 39, 40). Similarly, growing
evidence strongly suggests that MRD detection by multiparametric ﬂow cytometry (MFC), molecular techniques, or
chimerism analyses after allo-HSCT may be used as a
predictor of imminent relapse (41). These should be part of
routine post-transplant follow-up since MRD detection can
improve outcomes by guiding subsequent therapy aiming to
unleash or enhance the GVL effect (39).
Dynamic MRD monitoring after allo-HSCT may improve
outcomes; however, there is a relative paucity of data and lack of
clear recommendation on how we should test MRD (frequency,
qualitative and/or quantitative, on peripheral blood or bone
marrow), when we should react and what could be the best
available MRD-directed intervention post-allo HSCT (42).
The main methods for detection of MRD in patients with AML
after allo-HSCT are MFC, molecular genetics and chimerism
analyses (43). MFC is the standard and most commonly used
MRD method to identify residual leukemic cells reaching a
sensitivity of 10 −3 to 10−5 (39–44). Several studies have
demonstrated a higher risk of relapse in AML patients with
positive MRD detected by MFC after transplant compared to
those without evidence of MRD (≤ 0.1% leukemia cells) by the
same detection method (45, 46). MRD by ﬂow cytometry has many
drawbacks including the lack of standardization, its lower
sensitivity, the need for high technical expertise to differentiate
between leukemic from regenerating bone marrow cells, biological
heterogeneity of the leukemic population and the possibility of false
negative results related to sample processing, hemodilution, number
of events analyzed and immunophenotypic switch (45–47).
Another method of MRD assessment is donor/recipient
chimerism analysis that can detect host-derived hematopoiesis
based on genomic differences between the recipient and the
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patients with sustained low WT1 levels after transplant have
excellent outcomes (62).
Other emerging technologies like digital-droplet based PCR
and next-generation sequencing (NGS) assays are expected to be
particularly useful in AML (63–65).

donor. Decrease in donor chimerism in AML is often associated
with disease relapse (48). Sensitivity of chimerism is dependent on
the method applied, ranging from only 10−2–10−3 in the
conventional method using fragment analysis of short tandem
repeats (STR) or in XY-FISH analysis method in sex-mismatched
donor/recipient, to a high sensitivity of 10−4–10−5 if variant-allelespeciﬁc quantitative PCR that can detect small DNA insertions or
deletion or evaluation of CD34+ cell subset in AML were used (48–
50). In consequence, chimerism analysis should be routinely
performed after allo-HSCT on days +30, +100, +270, and +365 in
conjunction with other MRD markers and clinical parameters to
wisely decide on preemptive intervention (51).
The last method of MRD assessment is molecular analysis.
Currently, the most widely applied strategy for molecular MRD
monitoring is real-time quantitative PCR (RQ-PCR) which can
detect mutated genes, fusion gene transcripts or overexpressed
genes and can detect leukemic cells at 10−6 sensitivity (42, 43).
PCR based methods are characterized by high speciﬁcity and
sensitivity for leukemic cells detection and low risk of
contamination; however, their use depends on identifying
pretreatment AML-associated mutation at diagnosis and these
molecular targets must be stable while on therapy (52, 53). For
instance, some mutations like NPM1 mutation, RUNX1RUNX1T1 and CBF-MYH11 in core binding factor (CBF)
AML are relatively stable during disease course hereby are
suitable for PCR MRD monitoring (12). It was recently shown
that NPM1 MRD-positivity at levels >0.1% to >10% beyond Day
+60 post allo-HSCT are associated with increased relapse rates
and reduced survival. Hence, preemptive interventions are
considered for patients with persistent NPM1 MRD levels at
>0.1%–1% and more intervention should be considered if MRD
is >10% (54, 55). Persistent CBF-fusion transcripts after alloHSCT are translated into higher cumulative relapse incidence
(RI) and shorter leukemia-free survival (LFS). Thus, preemptive
interventions should be considered in case of persistent MRD
positivity (>1%) of RUNX1–RUNX1T1 or CBFB-MYH11 in two
consecutive measurements or if there is >0.5 log increase in the
transcripts in repeated analysis (56, 57).
Other mutations such as FLT3 (ITD and TKD), RAS, IDH1,
IDH2, and MLL-PTD may theoretically be measurable by MRD
detection but are poor MRD markers and have not been
integrated into routine care yet, since these mutations are
relatively unstable throughout treatment. Moreover, some of
these mutations are lost during disease course and treatment
due to leukemia clonal evolution (58). As a result, ELN guidelines
recommend against using them as single markers (39).
In contrast to the limited frequency (50%) of mutations
mentioned above, over-expression of Wilms Tumor 1 (WT1)
gene is present in almost 90% of patients with AML and can be
measured in peripheral blood with better sensitivity and
speciﬁcity than in bone marrow. WT1 expression analysis in
MRD assessment is recommended by ELN using a standardized
and certiﬁed ELN assay (59). Several reports showed that
persistent high bone marrow or continuous increase in
peripheral blood WT1 transcripts at 3 months post-transplant
are associated with higher risk of relapse (60, 61). Conversely,
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Hypomethylating Agents as Maintenance
Therapy After Allo-HSCT in AML
Table 1 summaries the studies that use HMA for relapse
prevention after allo-HSCT in AML. HMAs are clinically
active in AML and myelodysplastic syndromes (MDS) and
represent an important new treatment modality, particularly in
elderly and/or unﬁt patients, due to their favorable toxicity
proﬁle (77). HMA have signiﬁcant antitumor activity in relapsed
AML patients after allo-HSCT with a 20%–40% CR rate (78, 79).
Azacitidine (AZA) which is the ﬁrst reported DNMT inhibitor,
appears to be well tolerated after transplantation. In vitro and
murine studies showed that AZA has an important immunologic
effect after transplantation in expanding circulating Treg cells and
up-regulating the expression of tumor antigens on leukemic blasts
leading to increased GVL effect without increasing the risk of
GVHD (33).

Prophylactic Therapy With HMA After
Allo-HSCT
AZA and decitabine have been tested in several prospective and
retrospective studies as maintenance therapy to avoid relapse postallo-HSCT. These early-phase studies generally demonstrated
tolerability, feasibility and established the optimal dosage and
schedule for future trials (66, 68–72, 74–76). de Lima et al. (66)
reported the results of the ﬁrst phase 1 dose-ﬁnding study of
maintenance AZA post-transplant in 45 patients with high-risk
AML (n = 37) or MDS (n = 8). The investigators examined
subcutaneous AZA at different dosing schedule (8, 16, 24, 32, and
40 mg/m2). The optimal dose was 32 mg/m2 given for 5 consecutive
days every 28 days. After a median follow up of 20.5 months, the
NRM was 9%. One-year event-free survival (EFS) and 1-year OS
were 58% and 77%, respectively. The rates of grade II-III acute
GVHD and chronic GVHD were 27% and 37%, respectively. The
authors concluded that low dose azacitidine is safe and may prolong
OS and EFS in heavily pretreated AML and MDS patients as posttransplant maintenance (66).
In another report by Oshikawa and colleagues (68), AZA plus
gemtuzumab ozogamicin (GO) were used in 10 patients with highrisk AML after allo-HSCT. After a median follow-up of 474 days
from allo-HSCT, the NRM rate was 10% and the 1-year disease-free
survival (DFS) and OS were 60% and 70%, respectively (68).
Furthermore, in a prospective trial by Craddock et al. (71), 37
AML patients received AZA at a median time of 54 days posttransplant and at a dose of 36 mg/m2/day for 5 days every 28 days
up to 12 months. AZA was well tolerated in the majority of patients.
Only 17 patients had grade I–II acute GVHD. Day 100 and 1-year
NRM were 0% and 8%, respectively. The 1-year and 2-year OS were
81% and 49%, respectively (71).
Moreover, El-Cheikh and colleagues (72) reported their
results of an observational study on AML (n = 13) and MDS
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HMA

Study design

de Lima et al. (66)

AZA

Platzbecker et al. (67)
RELAZA trial

AZA

Oshikawa et al. (68)

AZA

Pusic et al. (69)

DAC

Prospective dose ﬁnding

Han et al. (70)

DAC

Phase I

Craddock et al. (71)
RICAZA trial

AZA

Prospective

El Cheikh et al. (72)

AZA

Observational

Platzbecker et al. (73)
RELAZA 2

AZA

Oran et al. (74)

AZA

de Lima et al. (75)

CC486

Marini et al. (76)

AZA

Number of patients
(disease)

Phase I

45
(AML: 37;
MDS: 8)
Prospective
20
Preemptive (detection of MRD (AML: 17;
after transplant)
MDS: 3)
Retrospective matched cohort 10 (AML)
study
22
(AML:17;
MDS:5)
16
(AML:5;
MDS:11)
37 (AML)

18
(AML:13;
MDS:5)
Prospective
53
Phase II
(AML:48;
Preemptive (detection of MRD MDS:5)
after transplant)
RCT
187
AML/MDS
AZA (93)
Ct (94)
Prospective
30
Phase I/II
(AML: 26;
dose ﬁnding
MDS:4)
Retrospective
32
Pro: 21
Pre: 11

Median
age, yrs

Schedule

Median starting time

No of cycles
median

60 (24–73)

8, 16, 24, 32 and
40 mg/m2
d1–5
75 mg/m2
d1–7

+40

1–4

+169

4 (1–11)

+78

1.5 (1–4)

+50 to +100

5 (1–8)

+86

1–4

+54

3–10

58 (20–74)

GVHD incidence

Response

Acute GVHD
- 1-yr EFS: 58%
Grades II–III: 27%
- 1-yr OS: 77%
chronic GVHD: 37%
——
- 16 Patients (80%) responded
(increase or stable CD34+ with no
relapse)
——
- 1-yr OS (70% in AZA-GO group
vs. 59.8% in controls)
- 1-yr DFS (60% vs. 42.8%)
Acute GVHD
- 2-yr OS: 56%
grades I–II: 27%
- 2-yr DFS: 48%
grades III–IV: 9%
Chronic GVHD:
——–
12.5%

60 (40–71)

30 mg/m2 d1–7
+
GO 3 mg/m2 d 8
5, 7.5, 10 and 15
mg/m2
d1–5
5 mg/m2
d1–5
then individualized
36 mg/m2 d1.5

58 (16–65)

32 mg/m2 d1–5

+60

16 (1–45)

Acute GVHD ≧
̸
grade II: 28%

59 (52–69)

75 mg/m2
d1–7

——

Up to 24

Acute GVHD
grade III: 2%

- 1-yr RFS: 46%

57

32 mg/m2 d1–5

+42 to +100

4 (1–12)

——

64 (28–80)

150–300 mg d1–7
or d1–14

+42 to +84

9 (1–12)

Acute GVHD
grade III: 10%

Median RFS:
AZA: 2.07 yrs
Ct: 1.28 yrs
p = 0.43
- 1-yr OS: 86% (7-day cohort)
- 1-year OS: 81% (14-day cohort)

Pro:
58 (15–69)
Pre:
52 (30–63)

Pro: 32 mg/m2
d1–5
Pre: 75 mg/m2
d1–5/7

Pro: +116
Pre: +138

Pro:
6 (1–18)
Pre:
4 (4–22)

All GVHD:40%

49 (17–65)

59 (21–68)

49

Acute GVHD
grades I–II: 46%
grades III–IV: 0%

-

1-yr OS: 81%
2-yr OS: 49%
1-yr RFS:57%
2-yr RFS: 49%
1-yr OS: 70%
1-yr DFS: 63%

Pro:
- 1-yr OS: 100%
- 1-yr EFS: 95%
Pre:
- 1-yr OS: 82%
- 1-yr EFS: 54%

HMA, hypomethylating agent; AZA, 5-azacytidine; EFS, event-free survival; OS, overall survival; GO, gemtuzumab ozogamicin; DFS, disease-free survival; DAC, decitabine; RFS, relapse-free survival; RCT, randomized controlled study; pts,
patients; Ct, control arm; yrs, years; pro, prophylaxis; pre, preemptive.

AML Relapse Prevention After Allo-HSCT

November 2020 | Volume 10 | Article 596134

Reference

Antar et al.

Frontiers in Oncology | www.frontiersin.org

TABLE 1 | Studies using HMA for relapse prevention after allo-HSCT in AML.

Antar et al.

AML Relapse Prevention After Allo-HSCT

(n = 5) patients who received post-transplant reduced dose
AZA of 32 mg/m2/day for 5 days monthly, for up to ﬁve years.
At the time of last follow up, 13 patients were still alive in CR,
and had full donor chimerism. The 1-year DFS and OS were
63% and 70%, respectively (72).
More recently, MD Anderson Cancer Center group reported
the results of ﬁrst randomized controlled trial (74). In this study,
187 patients with high-risk AML or MDS who were in CR after
allo-HSCT received AZA (n = 93) or placebo (n = 94) at a dose of
32 mg/m2/day for 5 days for 12 months. However, most of the
patients in the AZA arm (74.6%) did not receive the planned 12
cycles of treatment due to relapse, death, toxicity or upon
patient’s request. The investigators closed the study early due
to slow accrual. Relapse-free survival (RFS) was comparable
between both groups; however, stratiﬁcation by number of
AZA cycles administered showed a trend toward improved
RFS in patients receiving more AZA therapy cycles (74).
In addition to injectable AZA, an oral formulation of AZA
(CC-486) has been recently tested in a phase 1/2 dose-ﬁnding
study on 30 patients with AML (n = 26) and MDS (n = 4) in CR as
maintenance therapy after allo-HSCT (75). The study included
4 dosing schedules of 150-300 mg per day for 7 or 14 days every
28 days for up to 12 cycles. Oral AZA (CC-486) seemed safe and
generally well tolerated with only 3 patients (10%) developing
grade III acute GVHD. Median OS was not reached after
19 months follow-up and the 1-year OS were 86% and 81% in
the 7-day and 14-day dosing cohorts, respectively (75).
Decitabine is another HMA that has been evaluated in the
maintenance setting post allo-HSCT. Pusic et al. (69) tested the
safety and efﬁcacy of decitabine maintenance after allo-HSCT in 22
patients with AML (n = 17) and MDS (n = 5). Decitabine was given
at a dose of 5, 7.5, 10, and 15 mg/m2/day for 5 consecutive days
every 6 weeks. The toxicity proﬁle was acceptable. Acute GVHD
grade I-II and grade III–IV occurred in 27% and 9%, respectively.
The 2-year DFS and OS were 48% and 56%, respectively. The
investigators concluded that the dose of 10 mg/m2 for 5 days every 6
weeks appeared safe and optimal rather than the 15 mg/m2 and
could be administered after transplant in high-risk patients (69).
In another study, decitabine was evaluated in a phase 1 doseﬁnding study as maintenance therapy post allo-HSCT in 16
patients with MDS (n = 11) or secondary AML (n = 5) (70). No
aggravation of preexisting acute GVHD was observed and mild/
moderate chronic GVHD occurred in only 2 patients (12.5%). In
conclusion, the investigators considered 5 mg/m2/day to be the
most appropriate starting dose for decitabine maintenance (70).

(80%) had response with either increasing CD34+ donor chimerism
to >80% (n = 10; 50%) or stabilization (n = 6; 30%) with no evidence
of relapse. Furthermore, 11 patients (55%) with stable disease or
with subsequent drop in donor chimerism to <80% after initial
response received a median of 4 (range: 1–11) additional cycles of
AZA. Most patients (65%) ultimately developed hematologic
relapse but their relapse was delayed by a median of 231 days
after the decrease in donor chimerism.
In the second prospective trial (RELAZA-2) (73), 53 AML/MDS
patients who developed MRD positivity after transplant (n = 24) or
after conventional chemotherapy (n = 29) received AZA at a dose of
75 mg/m2/day for 7 days monthly for up to 24 cycles. MRD
positivity were deﬁned by a drop of 80% or less in CD34+ donor
chimerism or an increase in NPM1 mutation, RUNX1-RUNX1T1
and CBFb–MYH11 >1% in the bone marrow or peripheral blood
without evidence of hematological relapse. One-year RFS was 46%,
and 26 (49%) patients eventually relapsed. The authors concluded
that AZA could be effectively used to prevent or delay hematologic
relapse in MRD-positive patients with AML/MDS (73).
Overall, these data clearly show that AML patients can
tolerate maintenance therapy after allo-HSCT with HMA
(azacitidine or decitabine) albeit at lower doses, with a
favorable safety proﬁle and apparently a reduction in the risk
of disease relapse after transplant. Moreover, the results of
preemptive studies could serve as the basis to design future
studies of MRD-guided therapy using HMAs with other targeted
therapies, including immuno-modulating agents.

FLT3 Inhibitors as Maintenance Therapy
After Allo-HSCT in AML
Table 2 summaries the studies that use FLT3 inhibitors for relapse
prevention after allo-HSCT in AML. FLT3-internal tandem
duplication (ITD) mutation is found in approximately 30% of
patients with AML (91, 92). These patients have a high risk of
relapse and low cure rates (93, 94). Patients with FLT3-ITD
mutation also have a higher risk of early relapse after allo-HSCT
compared to patients with wild type FLT3 (38% vs. 28% in Center
for International Blood and Marrow Transplant Research
(CIBMTR) analysis) (94, 95). Treatment options for patients with
FLT3-mutated AML who relapse after transplant are limited to
chemotherapy, second allo-HSCT, and FLT3 inhibitors alone or
combined with DLI, all of which are rarely effective in the long term,
even though, a small fraction of those patients can achieve longstanding responses with sorafenib (22, 96–99). The use of FLT3
inhibitors as maintenance treatment after allo-HSCT is supported
by the observation of an anti-leukemic synergism between sorafenib
and allo-reactive donor cells (36, 37). Moreover, marrow aplasia
induced by chemotherapy leads to elevated FLT3-ligand levels that
may increase on-target activity of FLT3 inhibitors (100–103).
Sorafenib was the ﬁrst TKI studied in the setting of posttransplant maintenance therapy in AML with FLT3-ITD mutation.
It showed beneﬁt in survival and improvement of outcomes in a
phase I study, several retrospective studies and two randomized
studies (80–86, 104). Chen and colleagues (80) reported the results of
the ﬁrst phase I trial on sorafenib after transplant in 22 patients with
FLT3 mutated AML. They found that sorafenib could be safely used

Preemptive Therapy With HMA After
Allo-HSCT
MRD-triggered preemptive therapy with HMA is another strategy
to avoid relapse of AML after transplant. The German group has
tested this concept in 2 prospective studies (67, 73). The ﬁrst trial
was a single-center phase II study of 20 patients with MDS/AML
evaluating the administration of AZA preemptively post allo-HSCT
after a decrease of CD34+ donor chimerism to <80%, while still in
complete hematologic remission (67). All patients received AZA for
4 cycles at a dose of 75 mg/m2/day for 7 days. Sixteen-patients

Frontiers in Oncology | www.frontiersin.org
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TABLE 2 | Studies using FLT3 inhibitors for relapse prevention after allo-HSCT in AML.
Reference

FLT3 Inh

Study design

Phase 1
dose-ﬁnding
Retrospective
pilot study
Retrospective 2 arms

Patients number

Chen et al. (80)

Sorafenib

Antar et al. (81)

Sorafenib

Brunner et al. (82)

Sorafenib

Battipaglia et al.
(83, 84),

Sorafenib

Retrospective
Multi-center

28
(maintenance: 25,
salvage: 3)

Bazarbachi et al.
(85)

Sorafenib

Retrospective EBMT
registry-based analysis

Burchert et al. (86)
SORMAIN trial
Xuan et al. (87)

Sorafenib

Phase II prospective RCT

Sorafenib

Phase III randomized

Maziarz et al. (88)
Radius trial

Median age,
yrs

Schedule

22

54 (20–67)

6

50 (32–58)

80
(Sorafenib: 26;
Control: 54)

- Sorafenib:
54.5 (20–74)
- Control:
53 (25–72)
45 (16–57)

200–400 mg BID

462 (Prophylaxis:19;
preemptive:9; Control 434)

50 (19–75)

200–800 mg daily

83
Sorafenib: 43, Placebo: 40
202
Sorafenib: 100, Placebo:
102

54 (18–75)

200–400 mg BID for
up to 24 months
400 mg BID

Midostaurin Phase II randomized

60
Midostaurin + SOC: 30
Placebo + SOC: 30

18–70

50 mg BID for up to
12 months

Schlenk et al. (89)

Midostaurin Phase II
prospective

18–70

50 mg BID for 12
months

Sandmaier et al.
(90)

Quizartinib

134
(Midostaurin: 75,
Control:59)
13

43 (23–61)

40 mg daily (n = 7)
60 mg daily (n = 6)

Phase 1
Dose ﬁnding

18–60

200–400 mg BID for
12 months
400 mg BID
200–400 mg BID for
12–24 months

Response

- 2-yr OS: 78%
- 2-yr PFS: 72%
100% are alive after median
follow-up of 16 months
- 2-yr OS: sorafenib (81%),
control (62%) (S)
- 2-yr PFS: sorafenib (82%),
control (53%) (S)
- 1-yr OS: 89 ± 7%
- 1-yr LFS: 91 ± 6%
- 2-yr OS: 80 ± 8%
- 2-yr PFS: 73 ± 9%
Matched-pair analysis 26
sorafenib pts and 26 controls:
- 2-yr LFS: 79% (sorafenib) and
54% (control) (S)
- 2-yr OS: 83% (sorafenib) and
62% (control) (S)
- 2-yr RFS: 85% (sorafenib)
- 2-yr RFS: 53% (Placebo) (S)
- 2-yr LFS: 81% (sorafenib)
- 2-yr LFS: 54% (Placebo) (S)
- 2-yr OS: 83% (sorafenib)
- 2-yr OS: 72% (Placebo) (S)
- 1.5-yr RFS: 89% (midostaurin
+ SOC)
- 1.5-yr RFS: 76% (Placebo +
SOC)
Landmark analysis:
Better EFS and OS in
midostaurin pts (S)
- One relapse among 13
patients

Inh, inhibitor; yrs, years; OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; S, signiﬁcant; LFS, leukemia-free survival; RFS, relapse-free survival; SOC, standard
of care.

A recent update of this study after a median follow-up of 40 months
further demonstrated promising long-term outcomes with sorafenib
maintenance with 2-year PFS and OS of 73% and 80%, respectively.
Recently Bazarbachi and colleagues (85) reported the results of
European Society for Blood and Marrow Transplantation (EBMT)
registry-based study on 462 allo-grafted FLT3-mutated AML
patients (FLT3-ITD-95%) over a median follow-up of 39 months
for surviving patients. Among these patients, 28 received posttransplant sorafenib maintenance as prophylactic (n = 19) or
preemptive therapy (n = 9), started at a median of 55 days posttransplant (range 1–173 days) and a median dose of 800 mg/day
(range 200–800 mg/day). Multivariate analysis showed that
maintenance sorafenib signiﬁcantly decreased RI [hazard ratio
(HR) = 0.39; p = 0.05] with improvement in LFS (HR = 0.35;
p = 0.01) and OS (HR = 0.36; p = 0.03). A matched-pair analysis was
then performed on 52 patients (26 patients in the sorafenib group
and 26 in the control group). The 2-year LFS and OS were 79% and
83%, respectively, in the sorafenib group (p = 0.02) vs. 54% and
62%, respectively, in the control group (p = 0.007).
In a recent double-blind prospective trial (SORMAIN) (86),
83 transplanted FLT3-ITD adult AML patients were randomized
to receive either maintenance sorafenib (n = 43, up to 400 mg
twice daily) or placebo (n = 40) started between days 60 and 100

after allo-HSCT with a maximum tolerated dose (MTD) of 400 mg
twice daily. The 2-year progression-free survival (PFS) was 72% with
a corresponding 2-year OS of 78% after allo-HSCT. Our group has
reported the results of a pilot study in 6 patients with FLT3-ITD
AML who received sorafenib (n = 5 maintenance, n = 1 salvage) after
transplant. Grade II skin GVHD was observed in 5 of 6 patients
shortly after sorafenib initiation, suggesting a possible
immunomodulatory effect. Remarkably, all patients were alive after
a median follow-up of 16 months and had sustained molecular
remission (81). In a single institution observational study, sorafenib
maintenance was evaluated in patients with FLT3-ITD AML who
underwent allo-HSCT in CR1. Patients on sorafenib maintenance
(n = 26) had an improved 2-year OS (81% vs. 62%, p = 0.029)
and improved PFS (82% vs. 53%, p = 0.008) compared to historical
controls (n = 54) (82).
In a multicenter study, single agent sorafenib was used as posttransplant maintenance in 28 adults with FLT3 positive AML (83,
84). Twenty-ﬁve patients were given sorafenib as primary
prophylaxis and three patients received it after relapse post alloHSCT in combination with salvage chemotherapy and were then
continued as maintenance after achievement of CR. At a median
follow-up of 18 months, 25 patients were in CR with full donor
chimerism with 1-year DFS and OS of 91% and 89%, respectively.
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show better OS rates compared to salvage chemotherapy (27% vs.
15%). A total of 63 gilteritinib-treated patients had OS more than 18
months. A higher proportion of patients on gilteritinib achieved
remission and underwent allo-HSCT. After a median of 3.5 months,
35 of 63 (56%) patients underwent allo-HSCT; 25 of these 35
patients (71%) received post-transplant gilteritinib maintenance.
The authors concluded that the long-term survival in patients
receiving gilteritinib is related to ongoing remission, subsequent
allo-HSCT, or post-transplant gilteritinib maintenance therapy.
Gilteritinib is currently being prospectively tested as maintenance
therapy after allo-HSCT in FLT3-ITD AML patients in an ongoing
randomized, double-blind, placebo-controlled phase III trial
(NCT02997202) (109). This study aims to enroll and randomize
346 adult patients with AML in CR1 to receive maintenance therapy
with either 120 mg gilteritinib per day or placebo for 24 months.
Quizartinib, another selective and highly potent FLT3 inhibitor,
was also evaluated in a phase I dose-ﬁnding and safety study (90).
Thirteen adult patients with FLT3-ITD mutated AML in
morphological remission following allo-HSCT received one of two
quizartinib dose levels at 40 mg/day (n = 7) and 60 mg/day (n = 6),
administered orally for up to 24 months. Around 77% of patients
received quizartinib for at least 1 year and preliminary data
indicated an acceptable tolerability and a reduced relapse rate
compared with historical cohorts with only one (1/13) relapse.

after transplant for up to 24 months. The 2-year RFS was
signiﬁcantly improved in the sorafenib group (85%) compared to
the placebo group (53%) (HR = 0.39, 95% CI, 0.18 to 0.85 p = 0.01).
Sorafenib was generally well tolerated and the most common grade
III–IV adverse events was acute GVHD (20%) in sorafenib group
compared to (17%) in the placebo group.
More recently the Chinese group reported the results of a
phase III randomized open-label multi-centers trial on 202
FLT3-ITD AML adult patients who underwent allo-HSCT (87).
The patients received either sorafenib maintenance (n = 100; 400
mg BID) or placebo (n = 102) within 30–60 days post-transplant
and for 6 months. After median follow up of 22 months, eleven
and 30 patients relapsed in the sorafenib and control groups. The
2-year OS were 83% and 71%, (P = 0.025) and LFS were 81% and
54% (P < 0.001) in the sorafenib and control groups, respectively.
Acute Leukemia Working Party of the EBMT published a very
recent clinical practice recommendation on allo-HSCT in AML
patients with FLT3-ITD (105). The group recommends posttransplant maintenance with sorafenib in all cases except in
patients with active acute GVHD. Sorafenib should be started as
soon as possible after disease evaluation and MRD assessment at a
dose of 400 mg daily in two divided doses and the dose may be
increased to 800 mg daily in case of positive MRD and for a
minimum of 2 years, depending on tolerance.
Midostaurin is another FLT3 inhibitor that has activity as single
agent in AML harboring FLT3-ITD or FLT3 tyrosine kinase domain
(TKD) mutation. It was also evaluated in the maintenance setting.
Based on the RATIFY trial (106), midostaurin received FDA
approval in combination with 3 + 7 induction chemotherapy for
newly diagnosed FLT3-mutated AML. However, in this trial
midostaurin maintenance was not offered for patients who
underwent allo-HSCT.
The RADIUS phase II prospective trial randomized 60 patients
with FLT3-ITD AML to standard of care (n = 30) or midostaurin
(n = 30) starting 28–60 days post-transplant (88). The estimated RFS
at 18-month was 76% in the standard of care arm compared to 89% in
the midostaurin arm (HR = 0.46; 95% CI 0.12–1.86, P = 0.26),
corresponding to relapse rates of 24% and 11%, respectively (P = 0.27).
In another phase II prospective study by Schlenk et al. (89) on
284 newly diagnosed FLT3-ITD AML patients, midostaurin
maintenance treatment was also offered for patients receiving
allo-HSCT in CR1 (56%). In a landmark analysis in patients who
were event-free at day +100 after transplant (n = 116), those who
received maintenance therapy within 100 days post-transplant
(n = 72) had better EFS and OS (p = 0.004 and p = 0.01,
respectively) than patients who did not.
Gilteritinib is another potent inhibitor of FLT3 with activity
against FLT3-ITD and FLT3-TKD. In the phase 3 ADMIRAL trial,
371 adult patients with relapsed or refractory FLT3-mutated AML
were randomly assigned in a 2:1 ratio to receive either gilteritinib or
salvage chemotherapy. Patients who had a response and proceeded
to allo-HSCT continued in the trial and could resume gilteritinib as
maintenance therapy. Median OS in gilteritinib arm was 9.3 months
compared to 5.6 months in the chemotherapy arm (107). A follow
up on long-term survivors was recently presented in ASCO meeting
2020 (108). After 18 months of follow-up, gilteritinib continued to
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Future Perspective
Based on the previously discussed trials, introducing single agent
AZA as maintenance therapy can generally delay but mostly not
prevent relapse after allo-HSCT. Combining AZA with DLI is a
promising concept of MRD-guided post-transplant interventions
since it reduces disease burden by cytotoxic therapy and reinforce
an allo-immune reaction by cellular approach. This concept was
evaluated in a phase II study of 30 patients with high-risk AML
(n = 20) and MDS (n = 10) who were treated with prophylactic
post-transplant AZA followed by escalated doses of DLI. Two-year
OS and DFS were both 65.5%. Acute and chronic GVHD were
reported in 31.5% and 53% of patients, respectively (110).
Many targeted agents such as isocitrate dehydrogenase (IDH)
Inhibitors (IDH1, ivosidenib; IDH2, enasidenib), hedgehog (Hh)
inhibitor (glasdegib), and BCL2 inhibitor (venetoclax) in
combination therapy have been evaluated and showed
encouraging results in relapsed/refractory (R/R) AML or in AML/
MDS patients ineligible for intensive chemotherapy (111–117). Both
IDH inhibitors were approved by the FDA for the treatment of R/R
AML. These drugs induce cellular differentiation and may promote
an allo-immunologic reaction by antigen upregulation on leukemic
cells. This mode of action implies that these agents may have an
interesting activity in IDH-mutated AML patients as salvage or even
as maintenance therapy after transplant (111, 112). Currently, there
are several ongoing prospective trials evaluating the role of IDH
inhibitors in the maintenance setting after transplant in IDHmutated AML (NCT03515512 and NCT03564821). The safety
and efﬁcacy of combination venetoclax plus AZA in R/R AML
after allo-HSCT has been proven only in case series (113–116). The
same combination is being tested in post-transplant AML patients
as maintenance therapy (NCT04128501).
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Although combination HMA and FLT3 inhibitors was not
investigated in the setting of maintenance therapy after allo-HSCT
in AML, this combination has shown efﬁcacy in AML. DiNardo and
colleagues reported the results of the combination of venetoclax with
low dose AZA in 81 elderly patients; analysis of primary and adaptive
resistance was caused by an enrichment of clones harboring activated
signaling pathways such as FLT3 or RAS or biallelically perturbing
TP53 which helped in determining the predictors of outcome using
this combination therapy (117). And we know from previous studies
that combination of AZA plus sorafenib is effective and well tolerated
in relapsed/refractory FLT3-ITD AML (118). Thus, the combination
of FLT3 inhibitor and HMA seems to be a potential strategy to
prevent relapse post-transplant in high risk AML patients and it is
worth being investigated.
Hedgehog inhibitor (glasdegib) has recently shown promising
results in a randomized phase II study when combined with lowdose cytarabine (LDAC) as compared to LDAC alone in AML/
MDS frail patients (119). A single agent glasdegib is being
investigated in a phase II study as maintenance therapy
following allo-HSCT for high-risk patients (NCT01841333).
Finally, despite maintenance treatment, most of the patients
still relapse. Different mechanisms of resistance may emerge. For
example, in patients with FLT3-ITD mutation, acquisition of
point mutations in the FLT3 drug binding site, or activation of
alternative pathways such as mutations of the NRAS gene are the
most described mechanism of resistance.91 Many combinatorial
strategies have evolved and probably overcome this resistance
such as combination of FLT3-TKIs with epigenetic therapy
including histone deacetylase inhibitors and HMA, which
revealed promising and synergistic antileukemic in vitro
efﬁcacy mainly by downregulation of the JAK/STAT
pathway (120).
Figure 1 summarizes the treatment guidelines to prevent
relapse of AML after allo-HSCT.

Summary
• MRD measurement using MFC and RQ-PCR methods should
be incorporated in the treatment decision process for adult
AML patients after transplant.
• MRD will enable to identify high-risk patients to deﬁne
patients at risk of relapse who would beneﬁt from
preemptive approaches with HMA and targeted therapies.
• Azacitidine use as maintenance therapy in high-risk AML and
as preemptive MRD-triggered therapy could be considered
after transplant for at least 12 months at a dose of 32 mg/m2
for 5 days and 75 mg/m2 for 7 days, respectively.
• In FLT3-ITD AML patients, post-transplant maintenance
therapy with sorafenib at a dose 400–800 mg/day in
two divided doses should be strongly considered for
24 months.
• Other FLT3 inhibitors such as midostaurin and gilteritinib are
attractive in the maintenance setting and warrant further
investigation in larger prospective studies.
• The use of other agents (IDH inhibitors, BCL-2 inhibitors,
Hedgehog inhibitors) and combination therapy with DLI are
being evaluated and could have a promising result in the posttransplant maintenance setting.
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FIGURE 1 | Proposed treatment guidelines to prevent relapse of AML after allo-HSCT. MRD, measurable residual disease; IDH, isocitrate dehydrogenase; AZA,
azacitidine; DLI, donor lymphocyte infusion.
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of FLT3 internal tandem duplication on the outcome of related and
unrelated hematopoietic transplantation for adult acute myeloid leukemia
in ﬁrst remission: a retrospective analysis. J Clin Oncol (2012) 30:735–41.
doi: 10.1200/JCO.2011.36.9868
98. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, et al.
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after
allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow
Transplant (2011) 17:1874–7. doi: 10.1016/j.bbmt.2011.07.011
99. Sid S, Rey J, Charbonnier A, D’Incan E, Mohty B, Blaise D, et al. Treatment
of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine
and Sorafenib Bitherapy. Clin Lymph Myeloma Leuk (2017) 17:241–2. doi:
10.1016/j.clml.2016.10.002
100. Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand
impedes the efﬁcacy of FLT3 inhibitors in vitro and in vivo. Blood (2011)
117:3286–93. doi: 10.1182/blood-2010-01-266742
101. Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in
acute myeloid leukemia: ten frequently asked questions. Leukemia (2020)
34:682–96. doi: 10.1038/s41375-019-0694-3
102. Bazarbachi AH, Al Hamed R, Malard F, Mohty M, Bazarbachi A. Allogeneic
transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before,
during, and after transplant. Ther Adv Hematol (2019) 10:2040620719882666.
doi: 10.1177/2040620719882666
103. Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau É , Dumesnil C, et al.
How to prevent relapse after allogeneic hematopoietic stem cell transplantation in
patients with acute leukemia and myelodysplastic syndrome. Curr Res Transl Med
(2017) 65:65–9. doi: 10.1016/j.retram.2017.06.001
104. Antar A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, Battipaglia G,
Mahfouz R, et al. Inhibition of FLT3 in AML: a focus on sorafenib. Bone
Marrow Transplant (2017) 52:344–51. doi: 10.1038/bmt.2016.251
105. Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, et al. Clinical
practice recommendation on hematopoietic stem cell transplantation for
acute myeloid leukemia patients with FLT3-internal tandem duplication: a
position statement from the Acute Leukemia Working Party of the European
Society for Blood and Marrow Transplantation. Haematologica (2020)
105:1507–16. doi: 10.3324/haematol.2019.243410
106. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomﬁeld CD, et al.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3
Mutation. N Engl J Med (2017) 377:454–64. doi: 10.1056/NEJMoa1614359
107. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N
Engl J Med (2019) 381:1728–40. doi: 10.1056/NEJMoa1902688
108. Perl AE, Martinelli G, Neubauer A, Berman E, Baer MR, Larson RA, et al.
Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated
R/R AML: ADMIRAL trial follow-up. J Clin Oncol (2020) 38:7514. doi:
10.1200/JCO.2020.38.15_suppl.7514
109. Levis MJ, Hamadani M, Logan B, Rosales M, Perl AE, Devine SM, et al. A
phase 3, trial of gilteritinib, as maintenance therapy after allogeneic

Frontiers in Oncology | www.frontiersin.org

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.
J Clin Oncol (2018) 36(15_Suppl):TPS7075. doi: 10.1200/JCO.2018.36.
15_suppl.TPS7075
Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, et al.
Prospective phase II study of prophylactic low-dose azacitidine and donor
lymphocyte infusions following allogeneic hematopoietic stem cell
transplantation for high-risk acute myeloid leukemia and myelodysplastic
syndrome. Bone Marrow Transplant (2019) 54:1815–26. doi: 10.1038/
s41409-019-0536-y
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or
Refractory AML. N Engl J Med (2018) 378:2386–98. doi: 10.1056/
NEJMoa1716984
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al.
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Blood. (2017) 130:722–31. doi: 10.1182/blood-2017-04-779405
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al.
Clinical experience with the BCL2-inhibitor venetoclax in combination
therapy for relapsed and refractory acute myeloid leukemia and related
myeloid malignancies. Am J Hematol (2018) 93:401–7. doi: 10.1002/
ajh.25000
Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, et al. Efﬁcacy of
the combination of venetoclax and hypomethylating agents in relapsed/
refractory acute myeloid leukemia. Haematologica (2018) 103:e404–7. doi:
10.3324/haematol.2018.188094
Moukalled N, El Darsa H, Haibe Y, Massoud R, Kanj SS, Mahfouz R, et al.
Feasibility of Venetoclax-based combinations for adult patients with acute
myeloid leukemia relapsing after allogenic stem cell transplantation. Bone
Marrow Transplant (2019) 54:620–4. doi: 10.1038/s41409-018-0347-6
Vigil C, Silverman M, Carter T. Hypomethylating Agents and Low-Dose
Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell
Transplantation. Biol Blood Marrow Transplant (2020) 26:S104. doi:
10.1016/j.bbmt.2019.12.608
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al.
Molecular patterns of response and treatment failure after frontline
venetoclax combinations in older patients with AML. Blood (2020)
135:791–803. doi: 10.1182/blood.2019003988
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA,
et al. Phase II study of azacytidine plus sorafenib in patients with acute
myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood
(2013) 121:4655–62. doi: 10.1182/blood-2013-01-480228
Cortes JE, Heidel FH, Heuser M, Fiedler W, Smith BD, Robak T. A phase 2
randomized study of low dose Ara-C with or without Glasdegib (PF04449913) in untreated patients with acute myeloid leukemia or high-risk
myelodysplastic syndrome. Blood (2016) 128:99. doi: 10.1182/blood.
V128.22.99.99
Al-Jamal HAN, Jusoh SAM, Hassan R, Johan MF. Enhancing SHP-1
expression with 5-azacytidine may inhibit STAT3 activa- tion and confer
sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute
myeloid leukemia. BMC Cancer (2015) 15:869. doi: 10.1186/s12885-0151695-x

Conﬂict of Interest: The authors declare that the research was conducted in the
absence of any commercial or ﬁnancial relationships that could be construed as a
potential conﬂict of interest.
Copyright © 2020 Antar, Otrock, Abou Dalle, El-Cheikh and Bazarbachi. This is an
open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.

12

November 2020 | Volume 10 | Article 596134

